Regeneus (RGS) Stock Price, News & Analysis

Company Overview

Regeneus Ltd, a clinical stage regenerative medicine company, develops cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain, and dermatology diseases in Australia. The company's platform technology includes Progenza, a multi-synergistic therapy, which has completed Phase I clinical trial for the treatment of osteoarthritis; and in pre-clinical stage to treat neuropathic pain. It also develops Sygenus that is in pre-clinical stage for the treatment of skin wound healing. The company was incorporated in 2007 and is headquartered in Paddington, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 13,076 shs
• Average Volume: N/A
• Market Capitalization: A$3.68 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RGS Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Regeneus own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Regeneus investors own include American Rebel (AREB), Pacific Biosciences of California (PACB), Docusign (DOCU), SuperCom (SPCB), Zion Oil & Gas (ZNOG), CASI Pharmaceuticals (CASI) and Carvana (CVNA).

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Personal Services
• Current Symbol: ASX:RGS
• CIK: N/A
• Web: regeneus.com.au
• Phone: 61 2 9499 8010
• Fax: N/A
• Employees: 630
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$1.69 million
• Net Margins: -37.03%
• Pretax Margin: N/A
• Return on Equity: 455.81%
• Return on Assets: -62.56%

Debt

• Debt-to-Equity Ratio: -19.12
• Current Ratio: 0.28
• Quick Ratio: 0.46

Sales & Book Value

• Annual Sales: A$1.02 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 21.67
• Book Value: A($0.01) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 306,440,000
• Free Float: N/A
• Market Cap: A$3.68 million
• Optionable: Not Optionable
• Beta: -0.24